Artios is a leading independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Artios began clinical trials in February 2021 of its small-molecule ATR inhibitor, ART0380, in patients with advanced or metastatic solid tumours. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery and PARP inhibitors; key staff at Artios developed the drug olaparib (Lynparza ™). Artios is building a pipeline of next-generation DDR programmes, including through a unique partnership with Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK (CRUK), with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK.